Distribution and clinical characteristics of patients with and without amyloidosis in the SpA and non-SpA cohorts
| SpA without amyloidosis | SpA and amyloidosis | P value | SpA and amyloidosis | Non-SpA and amyloidosis | P value | |
| N (%) | 106 348 (100) | 792 (100) | 792 (100) | 68 (100) | ||
| Mean age (SD) | 58.9 (15.4) | 55.8 (13.1) | <0.001 | 55.8 (13.1) | 65.4 (13.2) | <0.001 |
| Mean Charlson index (SD) | 1.14 (1.81) | 1.80 (1.34) | <0.001 | 1.80 (1.34) | 1.69 (1.18) | 0.477 |
| Average length of stay in days (SD) | 10.5 (15.3) | 12.7 (15.1) | <0.001 | 12.7 (15.1) | 10.3 (8.9) | 0.038 |
| Male n (%) | 70 792 (66.5) | 596 (75.2) | <0.001 | 596 (75.2) | 43 (58.1) | 0.002 |
| Death during admission, n (%) | 3537 (3.3) | 82 (10.3) | <0.001 | 82 (10.3) | 5 (6.8) | 0.329 |
| Ankylosing spondylitis (%) | 67 207 (63.1) | 538 (67.9) | <0.001 | 538 (67.9) | NA | |
| Psoriatic arthritis (%) | 37 673 (35.4) | 243 (30.6) | 0.005 | 243 (30.6) | NA | |
| Spondyloarthritis-associated inflammatory bowel disease (%) | 5238 (4.9) | 81 (10.2) | <0.001 | 81 (10.2) | NA | |
| Reactive arthritis (%) | 2178 (2.0) | 20 (2.5) | 0.318 | 20 (2.5) | NA | |
| Uveitis (%) | 542 (0.5) | 12 (1.5) | <0.001 | 12 (1.5) | 0 (0) | |
| Diabetes mellitus (%) | 14 822 (13.9) | 34 (4.3) | <0.001 | 34 (4.3) | 5 (6.8) | 0.378 |
| Dementia (%) | 626 (0.6) | 3 (0.4) | 0.638 | 3 (0.4) | 3 (4.1) | 0.01 |
| Hypertension (%) | 31 395 (29.5) | 185 (23.3) | <0.001 | 185 (23.3) | 16 (21.6) | 0.886 |
| Smoking (%) | 13 283 (12.4) | 56 (7.1) | <0.001 | 56 (7.1) | 3 (4.1) | 0.469 |
| Hyperlipidaemia (%) | 17 748 (16.6) | 99 (12.5) | <0.001 | 99 (12.5) | 15 (20.3) | 0.071 |
| Obesity (%) | 1323 (1.2) | 3 (0.4) | 0.023 | 3 (0.4) | 0 (0) | 0.1 |
| Deep vein thrombosis (%) | 648 (0.6) | 7 (0.9) | 0.351 | 7 (0.9) | 1 (1.4) | 0.512 |
| Depression (%) | 5939 (5.6) | 23 (2.9) | <0.001 | 23 (2.9) | 6 (8.1) | 0.031 |
| Tuberculosis (%) | 544 (0.5) | 3 (0.4) | 0.803 | 3 (0.4) | 1 (1.4) | 0.416 |
bold, p<0.05; SpA, spondyloarthritis.